MC
FMTX

Matisse Capital’s Forma Therapeutics Holdings, Inc. Common Stock FMTX Stock Holding History

Matisse Capital’s Portfolio FMTX Stock Details FMTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-10,200
Closed -$237K – 169
2021
Q3 		$237K Sell
10,200
-300
-3% -$7.09K 0.09% 133
2021
Q2 		$261K Buy
+10,500
New +$282K 0.08% 129

Other funds holding FMTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Matisse Capital's FMTX Position: Q4 2021 in Review

Matisse Capital sold out of Forma Therapeutics Holdings, Inc. Common Stock (FMTX) in Q4 2021, closing a stake of 10,200 shares — an estimated $237K sold.

Matisse Capital first reported a position in FMTX in Q2 2021 and held it in 2 quarters. The position peaked at $261K in Q2 2021. 93 funds tracked by Wall St. Rank hold FMTX as of Q4 2021.

  • Matisse Capital reported no remaining Forma Therapeutics Holdings, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Matisse Capital sold 10,200 Forma Therapeutics Holdings, Inc. Common Stock shares in Q4 2021, an estimated $237K.
  • Matisse Capital first reported a position in Forma Therapeutics Holdings, Inc. Common Stock in Q2 2021 and held it in 2 quarters.
  • Matisse Capital's Forma Therapeutics Holdings, Inc. Common Stock position peaked at $261K in Q2 2021.
  • 93 funds tracked by Wall St. Rank held Forma Therapeutics Holdings, Inc. Common Stock as of Q4 2021.

Based on Matisse Capital's 13F filing for Q4 2021, filed 4 Feb 2022.